RT Generic
T1 Evidence of the Anti-Inflammatory Effects of Probiotics and Synbiotics in Intestinal Chronic Diseases
A1 Plaza-Diaz, Julio
A1 Javier Ruiz-Ojeda, Francisco
A1 Maria Vilchez-Padial, Laura
A1 Gil, Angel
K1 probiotics
K1 intestinal diseases
K1 anti-inflammatory effects
K1 inflammatory bowel diseases
K1 Inflammatory-bowel-disease
K1 Active ulcerative-colitis
K1 Enterotoxigenic escherichia-coli
K1 Human dendritic cells
K1 Lactobacillus-rhamnosus
K1 Controlled-trial
K1 Crohns-disease
K1 Mouse model
K1 Rat model
K1 Kappa-b
AB Probiotics and synbiotics are used to treat chronic diseases, principally due to their role in immune system modulation and the anti-inflammatory response. The present study reviewed the effects of probiotics and synbiotics on intestinal chronic diseases in in vitro, animal, and human studies, particularly in randomized clinical trials. The selected probiotics exhibit in vitro anti-inflammatory properties. Probiotic strains and cell-free supernatants reduced the expression of pro-inflammatory cytokines via action that is principally mediated by toll-like receptors. Probiotic administration improved the clinical symptoms, histological alterations, and mucus production in most of the evaluated animal studies, but some results suggest that caution should be taken when administering these agents in the relapse stages of IBD. In addition, no effects on chronic enteropathies were reported. Probiotic supplementation appears to be potentially well tolerated, effective, and safe in patients with IBD, in both CD and UC. Indeed, probiotics such as Bifidobacterium longum 536 improved the clinical symptoms in patients with mild to moderate active UC. Although it has been proposed that probiotics can provide benefits in certain conditions, the risks and benefits should be carefully assessed before initiating any therapy in patients with IBD. For this reason, further studies are required to understand the precise mechanism by which probiotics and synbiotics affect these diseases.
PB Mdpi ag
SN 2072-6643
YR 2017
FD 2017-06-01
LK http://hdl.handle.net/10668/19314
UL http://hdl.handle.net/10668/19314
LA en
DS RISalud
RD Apr 17, 2025